The Importance of Aprotinin and Pentoxifylline in Preventing Leukocyte Sequestration and Lung Injury Caused by Protamine at the End of Cardiopulmonary Bypass Surgery

Abstract

Background: Protamine has adverse effects on pulmonary gas exchange during the postoperative period. The objective of this study was to investigate the importance of aprotinin and pentoxifylline in preventing the leukocyte sequestration and lung injury caused by protamine administered after the termination of cardiopulmonary bypass (CPB). Methods: Participants (n = 39) were allocated into three groups at the termination of CPB: Group 1, (control group, n = 16); Group 2 (aprotinin group, n = 12), who received protamine + aprotinin (15 000 IU/kg); and Group 3 (Pentoxifylline group, n = 11), who received protamine + pentoxifylline (10 mg/kg). Leukocyte counts in pulmonary and radial arteries were determined after the termination of CPB and before any drug was given (t₁), and 5 minutes (t₂), 2 hours (t₃), 6 hours (t₄) and 12 hours (t₅) after the administration of protamine. Alveolar-arterial O₂ gradient (A-aO₂) and dynamic pulmonary compliance were measured at t₁, t₂ and t₃. Results: In the control group, an increase in pulmonary leukocyte sequestration was observed 5 minutes and 2 hours after protamine administration, after which this difference disappeared. No significant degree of pulmonary sequestration was detected in any measurements after protamine was administered in the aprotinin and pentoxifylline (PTX) groups. Dynamic lung compliance was 50.1, 45.2 and 47.2 ml/cm H₂O in the control group, 49.2, 61.1 and 56.3 ml/cm H₂O in the aprotinin group, and 49.5, 54.5 and 50.4 ml/cm H₂O in the PTX group. The A-aO₂ gradient was 212.2, 263.3 and 254.3 mm Hg in the control group, 209.4, 257.1 and 217.3 mm Hg in the aprotinin group, and 211.3, 260.8 and 219.2 mm Hg in the PTX group. Conclusion: Aprotinin and PTX treatments have favourable effects on lung function by reducing protamine-induced leukocyte sequestration into lungs at the end of CPB.

Cardiopulmonary bypass - protamine - aprotinin - pentoxifylline - alveolar-arterial O₂ gradient - dynamic compliance

References

• 1 Asimakopoulos G, Smith P LC, Ratnatunga C P, Taylor K M. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass.  Ann Thorac Surg. 1999;  68 1107-1115
• 2 Ng C S, Wan S, Yim A P, Arifi A A. Pulmonary dysfunction after cardiac surgery.  Chest. 2002;  121 1269-1277
• 3 Pugsley M K, Kalra V, Froebel-Wilson S. Protamine is a low molecular weight polycationic amine that produces actions on cardiac muscle.  Life Sci. 2002;  72 293-305
• 4 Butterworth J, Lin Y A, Prielipp R C, Bennett J, Hammon J W, James R L. Rapid disappearance of protamine in adults undergoing cardiac operation with cardiopulmonary bypass.  Ann Thorac Surg. 2002;  74 1589-1595
• 5 Kochamba G S, Yun K L, Pfeffer T A, Sintek C F, Khonsari S. Pulmonary abnormalities after coronary arterial bypass grafting operation: Cardiopulmonary bypass versus mechanical stabilization.  Ann Thorac Surg. 2000;  69 1466-1470
• 6 Singh N P, Vargas F S, Cukier A, Terra-Filho M, Teixeira L R, Light R W. Arterial blood gases after coronary artery bypass surgery.  Chest. 1992;  102 1337-1341
• 7 Rothenburger M, Trösch F, Markewitz A. et al . Leukocyte activation and phagocytotic activity in cardiac surgery and infection.  Cardiovasc Surg. 2002;  10 470-475
• 8 Hashimoto K, Miyamoto H, Suzuki K. et al . Evidence of organ damage after cardiopulmonary bypass. The role of elastase and vasoactive mediators.  J Thorac Cardiovasc Surg. 1992;  104 666-673
• 9 Dernek S, Tunerir B, Sevin B, Aslan R, Uyguc O, Kural T. The effects of methylprednisolone on complement, immunoglobulins and pulmonary neutrophil sequestration during cardiopulmonary bypass.  Cardiovasc Surg. 1999;  7 414-418
• 10 Rahman A, Üstünda B, Burma O, Ozercan I H, Cekirdekci A, Bayar M K. Does aprotinin reduce lung reperfusion damage after cardiopulmonary bypass?.  Eur J Cardiothorac Surg. 2000;  18 583-588
• 11 Creamer K M, McCloud L L, Fisher L E, Ehrhart I A. Pentoxifylline rescue preserves lung function in isolated canine lungs injured with phorbol myristate acetate.  Chest. 2001;  119 1893-1900
• 12 Landis R C, Asimakopoulos G, Poullis M, Haskard D O, Taylor K M. The antithrombotic and antiinflammatory mechanism of action of aprotinin.  Ann Thorac Surg. 2001;  72 2169-2175
• 13 Pruefer D, Makowski J, Dahm M. et al . Aprotinin inhibits leukocyte-endothelial cell interactions after hemorrhage and reperfusion.  Ann Thorac Surg. 2003;  75 210-216
• 14 Lord R A, Roath O S, Thompson J F, Chant A D, Francis J I. Effect of aprotinin on neutrophil function after major vascular surgery.  Br J Surg. 1992;  79 517-521
• 15 Müller J M, Vollmar B, Menger M D. Pentoxifylline reduces venular leukocyte adherence (“reflow paradox”) but not microvascular “no reflow” in hepatic ischemia/reperfusion.  J Surg Resc. 1997;  71 1-6
• 16 Sheridan B C, McIntyre R C, Meldrum D R, Fullerton D A. Pentoxifylline treatment attenuates pulmonary vasomotor dysfunction in acute lung injury.  J Surg Resc. 1997;  71 150-154
• 17 Boldt J, Brosch C, Lehmann A, Haisch G, Lang J, Isgro F. Prophylactic use of pentoxifylline on inflammation in elderly cardiac surgery patients.  Ann Thorac Surg. 2001;  71 1524-1529
• 18 Horiguchi T, Enzan K, Mitsuhata H, Murata M, Suzuki M. Heparin-protamine complexes cause pulmonary hypertension in goats.  Anesthesiology. 1995;  83 786-791
• 19 Sogawa M, Mohammad S F. Involvement of fibrinogen in protamine-induced pulmonary hypertension.  J Surg Res. 1997;  73 80-84
• 20 Pevni D, Frolkis I, Iaina A. et al . Protamine cardiotoxicity and nitric oxide.  Eur J Cardiothorac Surg. 2001;  20 147-152